Merck & Co.'s Keytruda, BioLineRx's Motixafortide Combine To Good Effect In Pancreatic Cancer
Keytruda Also Shown To Work With Eisai's Lenvima In Endometrial Cancer
BioLineRx's Phase IIa study of Keytruda/motixafortide/chemo showed improvements in overall and progression-free survival compared with historical data.
You may also be interested in...
Merck’s PD-1 inhibitor combined with Lenvima offered benefit in RCC, but use with Bristol’s Yervoy in metastatic NSCLC showed no benefit compared to Keytruda monotherapy.
The Israeli group is confident that its CXCR4 antagonist has potential as a platform molecule for a range of cancers at various stages of disease.
Analysts had forecast Q4 Roctavian sales of $5m-$6m, but they came in shy of $3m, and uptake has not yet come to reflect apparent demand.